KR20210104953A - Composition for relieving itching or inflammation caused by microdust - Google Patents

Abstract

The present disclosure relates to a composition for alleviating itching or inflammation caused by fine dust containing Oenothera odorata seed oil, a Sophora flavescens extract, and Chamaecyparis obtusa polysaccharide as active components. The composition can alleviate itching or inflammation caused by fine dust by inhibiting the production of IL-8, IL36γ, and PTGS2, and mast cell degranulation.

Description

Composition for relieving itching or inflammation caused by microdust}

The present specification relates to a composition for alleviating itching or inflammation caused by fine dust.

Recently, interest in fine dust has increased due to environmental issues, and the pollution market is expanding. Fine dust penetrates the human body better because it has smaller particles than general yellow dust, and it is harmful to the human body because it contains more harmful substances such as heavy metals, nitrates, ammonium, and sulfates. When fine dust enters our body, the cells responsible for the immune system of the human body act to remove the dust. In addition, the World Health Organization classifies fine dust as a group 1 carcinogen that is directly related to cancer.

Fine dust is expected to cause skin problems or itching by penetrating into the skin or hair follicles as well as the respiratory tract, but research on the mechanism and target of how it negatively affects the skin is insufficient.

Accordingly, it is necessary to develop an anti-pollution material capable of alleviating itching or inflammation caused by fine dust.

Korean Patent Publication No. 10-2019-0048613

In one aspect, the present invention is to provide a composition capable of alleviating itching or inflammation caused by fine dust.

In one aspect, the present invention provides a composition for alleviating itching or inflammation caused by fine dust comprising evening primrose seed oil, ginseng extract and cypress polysaccharide as active ingredients.

In an exemplary embodiment, the weight ratio of the evening primrose seed oil, the ginseng extract and the cypress polysaccharide may be 1: 0.01 to 100: 0.01 to 100.

In an exemplary embodiment, the content of the active ingredient may be 0.00001 to 10% by weight based on the total weight of the composition.

In an exemplary embodiment, the fine dust may include at least one of arsenic, cadmium, lead, and nickel.

In an exemplary embodiment, the particle size of the fine dust may be PM 10 or less.

In an exemplary embodiment, the active ingredient of the composition may be administered in a dosage of 0.1 to 70 mg/kg/day.

In an exemplary embodiment, the composition may be a food, pharmaceutical or cosmetic composition.

In one aspect, the composition for alleviating itching or inflammation caused by fine dust provided by the present invention can relieve itching or inflammation caused by fine dust without side effects.

1 is a graph showing the cytotoxicity of evening primrose seed oil, ginseng extract and cypress polysaccharide, respectively.
2 is a graph showing the cytotoxicity according to the concentration of evening primrose seed oil, ginseng extract and cypress polysaccharide mixture.
3 is a graph showing changes in IL-8 gene expression according to treatment with evening primrose seed oil, ginseng extract and cypress polysaccharide.
4 is a graph showing changes in IL36γ gene expression according to evening primrose seed oil, ginseng extract and cypress polysaccharide treatment.
5 is a graph showing changes in PTGS2 gene expression according to treatment with evening primrose seed oil, ginseng extract and cypress polysaccharide.
Figure 6 is a graph showing changes in mast cell degranulation (mast cell degranulation) according to the treatment of evening primrose seed oil, ginseng extract and cypress polysaccharide.

Hereinafter, the present invention will be described in detail.

In one aspect, the present invention provides a composition for alleviating itching or inflammation caused by fine dust comprising evening primrose seed oil, ginseng extract and cypress polysaccharide as active ingredients.

In the present specification, evening primrose ( Oenothera biennis ) is a dicotyledonous plant, a biennial herb in the family Apiaceae, a naturalized plant native to Chile, South America. Evening primrose contains an unsaturated fatty acid called gamma-linolenic acid (GLA), which is an essential intermediate in the biosynthesis of prostaglandins, which are physiologically active substances.

In one aspect, the evening primrose seed oil used as an active ingredient of the present invention is a vegetable oil extracted by pressing the seeds (seeds) of evening primrose, and may be prepared by a method known in the art, and the preparation method is not particularly limited. . For a specific example, after washing, drying, and roasting evening primrose seeds, the oil is extracted by pressing, and then filtered to prepare evening primrose seed oil.

In the present specification, old ginseng is the root of Sophora flavescens , which is a legume, a Tathagata seaweed, and has a peculiar smell and is persistent and has a very bitter and cold weakness. The high ginseng is used for dysentery, lobster, genital pruritus, and itchy skin due to hypothermia due to moist heat, and is used when there is pain due to inability to urinate due to bladder heat.

In one aspect, the high ginseng extract used as the active ingredient of the present invention can be prepared by extracting the high ginseng with water or an organic solvent by a method known in the art. The organic solvent may be one or more selected from the group consisting of ethanol, methanol, butanol, butylene glycol, ether, ethyl acetate and chloroform, or a mixed solvent of these organic solvents and water may be used. Preferably, a 50% butylene glycol aqueous solution may be used.

In the present specification, cypress polysaccharide is obtained by filtering the extract obtained by extracting the leaves of cypress ( Chamaecyparis obtuse ) with water to remove low-molecular-weight free protein, and separating the polysaccharide through a precipitation reaction. can be manufactured by, and the manufacturing method is not particularly limited.

In one embodiment, the weight ratio of the evening primrose seed oil, ginseng extract and cypress polysaccharide may be 1: 0.01 to 100: 0.01 to 100. Specifically, the weight ratio of the evening primrose oil, ginseng extract and cypress polysaccharide is 1: 0.01 to 100: 0.01 to 100, or 1: 0.1 to 50: 0.1 to 50, or 1: 0.1 to 20: 0.1 to 20, or 1: 0.1 to 10: 0.1 to 10, or 1: 1: 1. When the weight ratio of evening primrose seed oil, ginseng extract and cypress polysaccharide is out of the above range, the effect of alleviating itching or inflammation caused by fine dust is poor.

In one embodiment, the content of the active ingredient may be 0.00001 to 10% by weight based on the total weight of the composition. When the content of the active ingredient is less than 0.00001% by weight, the effect of alleviating itching or inflammation caused by fine dust is insignificant, and when the content of the active ingredient is more than 10% by weight, skin irritation may be severe. Specifically, the content of the active ingredient is 0.00001% by weight or more, 0.00003% by weight or more, 0.00005% by weight or more, 0.00007% by weight or more, 0.0001% by weight or more, 0.0003% by weight or more, 0.0005% by weight or more, 0.0007 based on the total weight of the composition. at least 0.001 wt%, at least 0.003 wt%, at least 0.005 wt%, at least 0.007 wt%, at least 0.01 wt%, at least 0.03 wt%, at least 0.05 wt%, at least 0.07 wt%, or at least 0.01 wt% , 10 wt% or less, 9 wt% or less, 8 wt% or less, 7 wt% or less, 6 wt% or less, 5 wt% or less, 4 wt% or less, 3 wt% or less, 2 wt% or less, 1 wt% or less , 0.9 wt% or less, 0.8 wt% or less, 0.7 wt% or less, 0.6 wt% or less, 0.5 wt% or less, 0.4 wt% or less, 0.3 wt% or less, 0.2 wt% or less, 0.1 wt% or less, 0.09 wt% or less , 0.08 wt% or less, 0.07 wt% or less, 0.06 wt% or less, 0.05 wt% or less, 0.04 wt% or less, or 0.03 wt% or less, but is not limited thereto.

One aspect of the present invention includes the use of the composition for alleviating itching or inflammation caused by fine dust.

In one embodiment, the composition can alleviate inflammation caused by fine dust by inhibiting the production of IL-8, IL36γ and PTGS2.

In one embodiment, the composition can alleviate itching caused by fine dust by inhibiting mast cell degranulation.

As used herein, the term “fine dust” refers to particulate matter that is invisible to our eyes and floats or scatters in the atmosphere for a long time. Specifically, the particle size of the fine dust may be 10 μm or less (PM 10), more specifically, 2.5 μm or less (PM 2.5). In particular, particulate matter having a particle diameter of 2.5 μm or less (PM 2.5) is referred to as “ultra-fine dust”, and “fine dust” is intended to include “ultra-fine dust” in the present specification.

In one aspect, the fine dust may include at least one of arsenic, cadmium, lead, and nickel. The heavy metal components such as arsenic, cadmium, lead, and nickel may be included in fine dust to attack skin cells and cause skin allergies, inflammation, and the like. In one embodiment, the fine dust may include one or more of arsenic, cadmium, lead, and nickel.

In one embodiment, the route of administration of the composition is not limited, but may preferably be transdermal or external skin application.

In one embodiment, the active ingredient of the composition may be administered in a dosage of 0.1 to 70 mg/kg/day. If the dosage of the active ingredient of the composition is less than 0.1 mg/kg/day, it may be difficult to exhibit the effect according to the present invention, and if it exceeds 70 mg/kg/day, it may cause irritation to the skin. Specifically, the active ingredient of the composition is 0.1 mg/kg/day or more, 0.2 mg/kg/day or more, 0.3 mg/kg/day or more, 0.4 mg/kg/day or more, 0.5 mg/kg/day or more, 0.6 mg/kg/day or more, 0.7 mg/kg/day or more, 0.8 mg/kg/day or more, 0.9 mg/kg/day or more, 1 mg/kg/day or more, 1.5 mg/kg/day or more, 2 mg/ ≥ kg/day, ≥ 2.5 mg/kg/day, ≥ 3 mg/kg/day, ≥ 3.5 mg/kg/day, ≥ 4 mg/kg/day, ≥ 4.5 mg/kg/day, ≥ 5 mg/kg/ ≥ 7 mg/kg/day or ≥ 10 mg/kg/day and ≤ 70 mg/kg/day, ≤ 67 mg/kg/day, ≤ 65 mg/kg/day, 63 mg/kg/day no more than 60 mg/kg/day, no more than 57 mg/kg/day, no more than 55 mg/kg/day, no more than 53 mg/kg/day, no more than 50 mg/kg/day, no more than 47 mg/kg/day, 45 mg/kg/day or less, 43 mg/kg/day or less, 40 mg/kg/day or less, 37 mg/kg/day or less, 35 mg/kg/day or less, 33 mg/kg/day or less, 30 mg /kg/day or less, 27 mg/kg/day or less, 25 mg/kg/day or less, 23 mg/kg/day or less, or 20 mg/kg/day or less.

In one embodiment, the composition may be a cosmetic composition. The cosmetic composition is, for example, softening lotion, astringent lotion, nourishing lotion, nourishing cream, massage cream, eye cream, eye essence, essence, cleansing cream, cleansing lotion, cleansing foam, cleansing water, pack, powder, body lotion , body cream, body essence, body cleaner, hair dye, shampoo, conditioner, hair dressing, hair conditioner, ointment, gel, cream, patch, spray, powder, and skin adhesion type, but are not limited thereto.

In addition, in each formulation, other components other than the above essential components can be suitably selected and formulated by those skilled in the art without difficulty depending on the type or purpose of use of other external preparations.

The cosmetic composition may be provided in any formulation suitable for topical application. For example, it may be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a microneedle, a foam, or an aerosol composition. have. Compositions of such formulations can be prepared according to conventional methods in the art.

The cosmetic composition according to the present specification may further include functional additives and components included in general cosmetic compositions in addition to the compounds of the present specification. The functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, and seaweed extract. The cosmetic composition according to the present specification may include other ingredients capable of giving a synergistic effect to the main effect, preferably within a range that does not impair the main effect. In addition, the cosmetic composition according to the present specification may further include a moisturizing agent, an emollient, a surfactant, a UV absorber, a preservative, a bactericide, an antioxidant, a pH adjuster, an organic and inorganic pigment, a fragrance, a cooling agent or a limiting agent. The blending amount of the component can be easily selected by those skilled in the art within the range that does not impair the purpose and effect of the present specification, and the blending amount may be 0.001 to 10% by weight, specifically 0.01 to 3% by weight, based on the total weight of the composition. have.

In one embodiment, the composition may be a food composition. The formulation of the food composition is not particularly limited, but, for example, may be formulated in tablets, granules, pills, powders, liquids such as drinks, caramel, gels, bars, tea bags, and the like. In addition to the active ingredient, the food composition of each dosage form can be appropriately selected by those skilled in the art without difficulty depending on the dosage form or purpose of use in addition to the active ingredient, and a synergistic effect may occur when applied simultaneously with other raw materials.

The food composition according to one embodiment includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, colorants and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and its salts. salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the food compositions according to an embodiment may include natural fruit juice and pulp for the production of fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The proportion of these additives is not so important, but is generally included in the range of 0 to about 50 parts by weight per 100 parts by weight of the composition according to an embodiment.

In one embodiment, the composition may be a pharmaceutical composition. The pharmaceutical composition may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously or the like. Formulations for oral administration may be tablets, pills, soft and hard capsules, granules, powders, fine granules, liquids, emulsions, or pellets, but are limited thereto it is not Formulations for parenteral administration may be solutions, suspensions, emulsions, gels, injections, drops, suppositories, patches, or sprays, but is not limited thereto. The formulation can be easily prepared according to conventional methods in the art, and surfactants, excipients, wettable powders, emulsification accelerators, suspending agents, salts or buffers for osmotic pressure control, coloring agents, spices, stabilizers, preservatives, preservatives or Other commercially available adjuvants may be further included.

Hereinafter, the present invention will be described in more detail through examples and the like. These examples are only for illustrating the present invention, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not to be construed as being limited by these examples.

[Preparation Example 1] Preparation of evening primrose seed oil

Evening primrose seeds, which are seeds of evening primrose ( Oenothera biennis ), were collected, washed, dried, roasted, and pressed to extract oil. The extracted oil was filtered (3㎛ → 1㎛ → 0.5㎛), precipitated at 4 ℃ for 1 day, then filtered again (0.3㎛) to obtain evening primrose seed oil.

[Preparation Example 2] Preparation of high ginseng extract

After washing and drying 1 kg of Korean ginseng root, a 50% aqueous butylene glycol solution was added, followed by extraction at 25° C. for 24 hours. After filtering the obtained extract using a 250 mesh filter, it was allowed to stand at 4°C for 3 days, and then filtered again (0.5㎛ → 0.3㎛ → 0.2㎛) to obtain a high ginseng extract.

[Preparation Example 3] Preparation of cypress polysaccharide

After washing 1 kg of dried cypress leaves, 10 liters of water was added and extracted at 18° C. for 24 hours. The obtained extract was filtered to remove low molecular weight free proteins, and ethanol (98%) twice the volume of the filtrate was slowly added at a rate of 100 ml/min to proceed with an ethanol precipitation reaction. The precipitate was freeze-dried to prepare a powder, and then the powder was dissolved in a mixed solution of 1,3-butylene glycol and water to obtain a cypress polysaccharide.

[Preparation Example 4] Preparation of evening primrose seed oil, ginseng extract and cypress polysaccharide mixture

Evening primrose seed oil of Preparation Example 1, high ginseng extract of Preparation Example 2, and Cypress polysaccharide of Preparation Example 3 were mixed in a weight ratio of 1:1:1 to prepare a mixture of evening primrose seed oil, high ginseng extract and cypress polysaccharide.

[Experimental Example 1] Culture of Normal Human Epidermal keratinocytes

A keratinocyte cell line (LONZA社, 192907) was cultured in a CO ₂ incubator _{(CO 2 incubator) 37 ℃,} 5% CO 2 conditions. As a medium, ^{Supplement (LONZA, 192060) was added to KGM-Gold TM} Keratinocyte Growth Medium, and Accutase (Merck Millipore, SCR005) was used for cell passage.

[Experimental Example 2] Cytotoxicity measurement experiment

The keratinocytes of Experimental Example 1 were inoculated in a 96-well plate at 20000 cells/well (cells/well), and then _{cultured at 37° C. under 5% CO 2} conditions for 24 hours. Herein, the evening primrose seed oil of Preparation Example 1, the high ginseng extract of Preparation Example 2, the cypress polysaccharide of Preparation Example 3, and the evening primrose seed oil of Preparation Example 4, the high ginseng extract and the mixture of the cypress polysaccharide of Preparation Example 4 were treated, respectively, and then 37° C., 5% for 24 hours. Incubated under CO _{2 conditions.} As a control group, an untreated group was used, and as a positive control group, a group treated with supplement-containing medium was used. After treatment with CCK-8 (DOJINDO, CK04-11) for 2 hours, absorbance was measured at 450 nm using a microplate reader, and the results are shown in FIGS. 1 and 2 .

As can be seen in FIGS. 1 and 2, evening primrose seed oil, high ginseng extract, and cypress polysaccharide did not show cytotoxicity up to 10 ppm, and the mixture of evening primrose seed oil, high ginseng extract and cypress polysaccharide had a cell viability of about 70% at 100 ppm, with a concentration of 100 ppm or higher. It was found that cytotoxicity appeared in some cases.

[Experimental Example 3] Inflammation marker gene expression level measurement experiment through qPCR

1. Treatment of fine dust and substances in keratinocytes

Fine dust was collected at a PM 2.5 level by installing a high volume sampler on the roof of the Amorepacific Research Institute. A PTFE Teflon filter was used, and it was collected for 24 hours at a flow rate of ^{1.13 m 3 /min.}

The keratinocytes of Experimental Example 1 were inoculated into a 6 well plate at 3 × 10 ⁵ cells/well (cells/well) and cultured. ), the group treated with fine dust and 1 ppm of evening primrose seed oil of Preparation Example 1, the group treated with fine dust and 1 ppm of the high ginseng extract of Preparation Example 2, the group treated with fine dust and 1 ppm of the cypress polysaccharide of Preparation Example 3, fine dust and A total of 7 groups were treated with 0.1 ppm of the evening primrose seed oil, ginseng extract and cypress polysaccharide mixture of Preparation Example 4, and 0.5 ppm of fine dust and evening primrose seed oil, high ginseng extract and cypress polysaccharide mixture of Preparation Example 4 processed.

2. qPCR Quantification

2-1. RNA extraction

The culture medium was removed from the 6 well plate treated with the material, and the cells were washed with 2 ml of phosphate buffer (Phosphate Buffered Saline, PBS), and then RNA in the cells was isolated using Trizol reagent (Invitrogen).

2-2. cDNA synthesis

cDNA was synthesized from the isolated RNA using a reverse transcription kit (Invitrogen, Superscript III).

2-3. Perform qPCR

The synthesized cDNA was quantitatively analyzed through quantitative polymerase chain reaction (qPCR) using IL-8, IL36γ, and PTGS2 probes, and the results are shown in FIGS. 3 to 5 .

As can be seen in FIG. 3 , in control group 2 treated with fine dust (PM2.5), IL-8, an inflammatory marker, showed a statistically significant increase in level, and the group treated with evening primrose oil, ginseng extract, and cypress polysaccharide 1ppm, respectively. showed no anti-inflammatory effect. On the other hand, in the group treated with evening primrose seed oil, ginseng extract and 0.5 ppm of cypress polysaccharide mixture, a statistically significant decrease in IL-8 was confirmed.

In addition, through FIGS. 4 and 5, the group treated with evening primrose seed oil, ginseng extract, and cypress polysaccharide respectively did not show a reduction effect on the inflammatory markers IL36γ and PTGS2 increased by the fine dust (PM2.5) treatment, but evening primrose seed oil, In the group treated with Korean ginseng extract and 0.5 ppm of cypress polysaccharide mixture, it was confirmed that IL36γ and PTGS2 increased by fine dust treatment were reduced to statistically significant levels.

Taken together, these results show that the composition comprising evening primrose seed oil, ginseng extract and cypress polysaccharide as active ingredients according to an embodiment of the present specification reduces IL-8, IL36γ, and PTGS2 and has an excellent effect in alleviating inflammation caused by fine dust. was found to be

[Experimental Example 4] Degranulation effect measurement experiment of mast cells (mast cells)

1. Culture of RBL-2H3 Cell Line

RBL-2H3 cells (basophil leukemia cell line) to the obtained from Korea Cell Line Bank (22 256) were cultured in a CO ₂ incubator (CO ₂ incubator), 37 ℃ from, 5% CO ₂ condition. As a medium, DMEM media (w/10% FBS, 1% antibiotics) was used.

2. Treatment of fine dust and substances in RBL-2H3 cell line

The RBL-2H3 was inoculated in a 96-well plate at 4 × 10 ⁴ cells/well (cells/well) and cultured, and then treated with DNP-lgE and DNP-BSA as controls (control group 1), DNP- Group treated with lgE, DNP-BSA and fine dust (control group 2), group treated with DNP-lgE, DNP-BSA, fine dust and Ketotifen (positive control), DNP-lgE, DNP-BSA, fine dust and manufacturing Group treated with 1 ppm of evening primrose seed oil of Example 1, DNP-lgE, DNP-BSA, fine dust and 1 ppm of high ginseng extract of Preparation Example 2, DNP-lgE, DNP-BSA, fine dust and cypress of Preparation Example 3 The group treated with 1 ppm of polysaccharide, DNP-lgE, DNP-BSA, fine dust, and the group treated with 0.1 ppm of the evening primrose seed oil, ginseng extract and cypress polysaccharide mixture of Preparation Example 4, and DNP-lgE, DNP-BSA, fine dust and A total of 8 groups were treated with 0.5 ppm of the evening primrose seed oil, ginseng extract and cypress polysaccharide mixture of Preparation Example 4, respectively. As the fine dust, fine dust collected in the same manner as in Experimental Example 3 was used.

3. Mast cell degranulation measurement (ß-hexosaminidase assay)

Above '2. In RBL-2H3 cell line, after incubating the cells treated with the substances in ‘Treatment of fine dust and substances’ in an incubator for 1 hour, transfer 50 μl sup from each well to a new 96 well plate, add 50 μl of substrate solution thereto, and incubate reacted for 1 hour. After confirming that it turns yellow by adding 100 μl of Stop solution, absorbance was measured at 405 nm, and the result is shown in FIG. 6 .

As can be seen in FIG. 6 , it was found that mast cell degranulation was increased when fine dust (PM 2.5) was co-treated compared to the group treated with DNP-lgE and DNP-BSA. This increased mast cell degranulation did not change in the group treated with evening primrose seed oil, high ginseng extract, and cypress polysaccharide, respectively, but it was decreased to a statistically significant level in the group treated with evening primrose seed oil, high ginseng extract, and 0.5 ppm of the mixture of cypress polysaccharide. .

[Formulation Example 1] Lotion

A lotion was prepared in a conventional manner according to the composition shown in Table 1 below.

ingredient content (wt%) Evening Primrose Oil 0.00002 Ginseng Extract 0.00002 Cypress Polysaccharide 0.00002 L-ascorbic acid-2-magnesium phosphate salt 1.00 Collagen 1.00 sodium citrate 0.10 citric acid 0.05 Licorice Extract 0.20 1,3-butylene glycol 3.00 Purified water remaining amount Sum 100.00

[Formulation Example 2] Cream

Creams were prepared in a conventional manner according to the composition shown in Table 2 below.

ingredient content (wt%) Evening Primrose Oil 0.00002 Ginseng Extract 0.00002 Cypress Polysaccharide 0.00002 Polyethylene glycol monostearate 2.00 Self-emulsifying glycerin monostearate 5.00 cetyl alcohol 4.00 squalene 6.00 tri2-glyceryl ethyl henate 6.00 sphingoglycolipids 1.00 1,3-butylene glycol 7.00 Purified water remaining amount Sum 100.00

[Formulation Example 3] Pack

A pack was prepared in a conventional manner according to the composition shown in Table 3 below.

ingredient content (wt%) Evening Primrose Oil 0.00002 Ginseng Extract 0.00002 Cypress Polysaccharide 0.00002 polyvinyl alcohol 13.00 L-ascorbic acid-2-magnesium phosphate salt 1.00 Lauroylhydroxyproline 1.00 Collagen 2.00 1,3-butylene glycol 3.00 ethanol 5.00 Purified water remaining amount Sum 100.00

[Formulation Example 4] Shampoo

A shampoo was prepared in a conventional manner according to the composition shown in Table 4 below.

ingredient content (wt%) Evening Primrose Oil 0.00002 Ginseng Extract 0.00002 Cypress Polysaccharide 0.00002 Sodium Liuryl Sulfate 10.00 cocamidor propyl betaine 3.00 carboxyl vinyl polymer 0.30 Polyquaternium-10 0.20 cetyltrimethylammonium chloride 0.10 Purified water remaining amount Sum 100.00

[Formulation Example 5] Rinse

A rinse was prepared in a conventional manner according to the composition shown in Table 5 below.

ingredient content (wt%) Evening Primrose Oil 0.00002 Ginseng Extract 0.00002 Cypress Polysaccharide 0.00002 cetyl alcohol 2.00 stearyl alcohol 2.50 behenyl alcohol 0.50 silicone emulsion 0.40 cyclomethicone 1.00 Dimethyldistearylammonium chloride 0.10 Purified water remaining amount Sum 100.00

[Formulation Example 6] Ointment

An ointment was prepared in a conventional manner according to the composition shown in Table 6 below.

ingredient content (wt%) Evening Primrose Oil 0.00002 Ginseng Extract 0.00002 Cypress Polysaccharide 0.00002 glycerin 8.00 butylene glycol 4.00 liquid paraffin 15.00 beta glucan 7.00 Carbomer 0.10 Caprylic/Capric Triglycerides 3.00 squalane 1.00 cetearyl glucoside 1.50 Soribitan Stearate 0.40 cetearyl alcohol 1.00 beeswax 4.00 Purified water remaining amount Sum 100.00

[Formulation Example 7] Hair Tonic

Hair tonic was prepared in a conventional manner according to the composition shown in Table 7 below.

ingredient content (wt%) Evening Primrose Oil 0.00002 Ginseng Extract 0.00002 Cypress Polysaccharide 0.00002 ethanol 55.00 castor oil 5.00 glycerin 3.00 pyroctonamine 0.10 fragrance, color 0.50 Purified water remaining amount Sum 100.00

[Formulation Example 8] Hair lotion

A hair lotion was prepared in a conventional manner according to the composition shown in Table 8 below.

ingredient content (wt%) Evening Primrose Oil 0.00002 Ginseng Extract 0.00002 Cypress Polysaccharide 0.00002 cetostearyl alcohol 2.00 Stearyltriethylammonium chloride 2.00 hydroxyethyl cellulose 0.50 pyroctonolamine 0.10 fragrance, color 0.50 Purified water remaining amount Sum 100.00

[Formulation Example 9] Soap

Soap was prepared in a conventional manner according to the composition shown in Table 9 below.

ingredient content (wt%) Evening Primrose Oil 0.000015 Ginseng Extract 0.000015 Cypress Polysaccharide 0.000015 titanium dioxide 0.20 polyethylene glycol 0.80 glycerin 0.50 Ethylenediaminetetraacetic acid 0.05 salt 1.00 pigment 0.20 soapy scent 0.20 soap base remaining amount Sum 100.00

[Formulation Example 10] Cosmetic liquid formulation

According to the composition shown in Table 10 below, a cosmetic liquid formulation was prepared by a conventional method.

ingredient content (wt%) Evening Primrose Oil 0.00002 Ginseng Extract 0.00002 Cypress Polysaccharide 0.00002 Hydroxyethylene Cellulose 12.00 xanthan gum 2.00 1,3-butylene glycol 6.00 glycerin 4.00 Sodium Hyaluronate 5.00 Purified water remaining amount Sum 100.00

[Formulation Example 11] Soft capsule preparation

Evening primrose oil 0.15 mg, ginseng extract 0.15 mg, cypress polysaccharide 0.15 mg, L-carnitine 80 mg, soybean oil 180 mg, palm oil 2 mg, hydrogenated vegetable oil 8 mg, yellow wax 4 mg and lecithin 6 mg are mixed, and filled into 1 capsule according to the usual method to make it soft. Capsules were prepared.

[Formulation Example 12] Tablet

After mixing 0.15 mg of evening primrose seed oil, 0.15 mg of ginseng extract, 0.15 mg of cypress polysaccharide, 200 mg of galactooligosaccharide, 60 mg of lactose and 140 mg of maltose, granulation using a fluidized bed dryer, 6 mg of sugar ester is added and pressed with a tablet press. to prepare tablets.

[Formulation Example 13] Granules

After mixing 0.15 mg of evening primrose seed oil, 0.15 mg of ginseng extract, 0.15 mg of cypress polysaccharide, 250 mg of anhydrous crystalline glucose, and 550 mg of starch, the mixture was formed into granules using a fluidized bed granulator, and then filled into a bag to prepare granules.

[Formulation Example 14] Drink agent

After mixing 0.15 mg of evening primrose oil, 0.15 mg of ginseng extract, 0.15 mg of cypress polysaccharide, 10 g of glucose, 0.6 g of citric acid, and 25 g of liquid oligosaccharide, add 300 ml of purified water and fill each bottle by 200 ml. After filling the bottle, it was sterilized at 130° C. for 4 to 5 seconds to prepare a drink beverage.

Claims (7)

A composition for alleviating itching or inflammation caused by fine dust comprising evening primrose seed oil, ginseng extract and cypress polysaccharide as active ingredients. According to claim 1,
The weight ratio of the evening primrose seed oil, ginseng extract and cypress polysaccharide is 1: 0.01 to 100: 0.01 to 100 composition. According to claim 1,
The content of the active ingredient is 0.00001 to 10% by weight of the composition based on the total weight of the composition. According to claim 1,
The fine dust is a composition comprising at least one of arsenic, cadmium, lead, and nickel. According to claim 1,
The fine dust is a composition having a particle size of 10 PM or less. According to claim 1,
The active ingredient of the composition is administered in a dosage of 0.1 to 70 mg/kg/day. According to claim 1,
The composition is a food, pharmaceutical or cosmetic composition.

Images